Literature DB >> 8431424

Molecular dynamics simulation of HIV-1 protease in a crystalline environment and in solution.

D M York1, T A Darden, L G Pedersen, M W Anderson.   

Abstract

Simulations of the unbound form of the human immunodeficiency virus type 1 protease have been carried out to 200 ps in a crystalline environment and in solution. Solution simulations were performed with and without charge-balancing counterions. The results are compared with the 2.8-A crystallographic structure of Wlodawer et al. [(1989) Science 245, 616], and a proposed model for the solution structure which involves local refolding of the flap regions is presented. The simulations suggest the crystal packing environment of the protease dimer stabilizes the flaps in an extended conformation. Solvation of the dimer leads to local refolding of the flaps which contract toward the active site, forming increased overlap and stronger intersubunit hydrogn bonding at the tips. The degree to which the flaps overlap in solution is observed to depend on the charge state of the system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431424     DOI: 10.1021/bi00057a007

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

1.  Atomic-level accuracy in simulations of large protein crystals.

Authors:  D M York; A Wlodawer; L G Pedersen; T A Darden
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

2.  Importance of explicit salt ions for protein stability in molecular dynamics simulation.

Authors:  G T Ibragimova; R C Wade
Journal:  Biophys J       Date:  1998-06       Impact factor: 4.033

3.  Trp42 rotamers report reduced flexibility when the inhibitor acetyl-pepstatin is bound to HIV-1 protease.

Authors:  B Ullrich; M Laberge; F Tölgyesi; Z Szeltner; L Polgár; J Fidy
Journal:  Protein Sci       Date:  2000-11       Impact factor: 6.725

4.  Understanding the effects on constitutive activation and drug binding of a D130N mutation in the β2 adrenergic receptor via molecular dynamics simulation.

Authors:  Yanyan Zhu; Yuan Yuan; Xiuchan Xiao; Liyun Zhang; Yanzhi Guo; Xuemei Pu
Journal:  J Mol Model       Date:  2014-10-25       Impact factor: 1.810

5.  On achieving better than 1-A accuracy in a simulation of a large protein: Streptomyces griseus protease A.

Authors:  D H Kitson; F Avbelj; J Moult; D T Nguyen; J E Mertz; D Hadzi; A T Hagler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

6.  Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations.

Authors:  Darón I Freedberg; Rieko Ishima; Jaison Jacob; Yun-Xing Wang; Irina Kustanovich; John M Louis; Dennis A Torchia
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

7.  NMR and MD studies combined to elucidate inhibitor and water interactions of HIV-1 protease and their modulations with resistance mutations.

Authors:  Rieko Ishima; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  J Biomol NMR       Date:  2019-06-26       Impact factor: 2.835

8.  Framework for Conducting and Analyzing Crystal Simulations of Nucleic Acids to Aid in Modern Force Field Evaluation.

Authors:  Şölen Ekesan; Darrin M York
Journal:  J Phys Chem B       Date:  2019-05-03       Impact factor: 2.991

9.  A de novo GRIN1 Variant Associated With Myoclonus and Developmental Delay: From Molecular Mechanism to Rescue Pharmacology.

Authors:  Jin Zhang; Weiting Tang; Nidhi K Bhatia; Yuchen Xu; Nabina Paudyal; Ding Liu; Sukhan Kim; Rui Song; Wenshu XiangWei; Gil Shaulsky; Scott J Myers; William Dobyns; Vasanthi Jayaraman; Stephen F Traynelis; Hongjie Yuan; Xiuhua Bozarth
Journal:  Front Genet       Date:  2021-08-03       Impact factor: 4.599

10.  (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity.

Authors:  Raymond G Booth; Lijuan Fang; Yingsu Huang; Andrzej Wilczynski; Sashikala Sivendran
Journal:  Eur J Pharmacol       Date:  2009-05-03       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.